FDA Approves Breakthrough Pancreatic Cancer Pill

The FDA on Wednesday granted expedited approval to a first-of-its-kind pill designed to treat the most common form of pancreatic cancer, one of the deadliest cancers in the United States. According to FDA officials, the drug, daraxonrasib, blocks a mutated protein responsible for fueling tumor growth in more than 90% of pancreatic cancer cases — a target that had eluded drugmakers for decades. The daily pill will be marketed by Revolution Medicines under the brand name Rasonque. The approval marks a significant advance in the fight against a cancer notorious for its low survival rates and limited treatment options. Health officials say the drug offers new hope for patients facing one of oncology's toughest diagnoses, though long-term outcomes data will continue to be studied as the treatment reaches wider use.